MMA and the Minnesota Society of Addiction Medicine Release 7-OH, Kratom Clinical Guidance

October 21, 2026

The MMA and the Minnesota Society of Addiction Medicine (MNSAM) are pleased to share a new clinical resource developed to support Minnesota clinicians caring for patients using concentrated 7-hydroxymitragynine (7-OH) and related kratom-derived products. The package provides practical guidance for assessment and buprenorphine initiation across inpatient, outpatient, and at-home settings. It is designed to help clinicians navigate an emerging area of practice where product potency and labeling may be unreliable, and the published treatment evidence remains limited.

The resource is intended to support, not replace, clinical judgment, and can be used as a practical starting point when evaluating and treating patients with suspected 7-OH or kratom-related dependence.

The 7-OH, Kratom Clinical Guidance can be found here.

Disclaimer

This guidance is intended solely for educational and information purposes to assist qualified healthcare professionals in the administration of buprenorphine. It does not constitute formal medical advice, establish a binding standard of care, replace the independent professional clinical judgment of the treating healthcare professional, or establish a doctor-patient relationship. Healthcare professionals must tailor treatment plans to the individual needs, medical history, and specific circumstances of each patient. Medical knowledge is constantly evolving, and it is the responsibility of the healthcare professional to stay informed of the latest clinical guidelines, safety alerts, and prescribing information issued by regulatory bodies and manufacturers. Healthcare professionals are also responsible for ensuring that their practice complies with local, state, and federal laws and regulations. Patients with health care related questions or concerns are advised to contact a physician or other qualified health care professional.

The Minnesota Medical Association shall not be liable for direct, indirect, special, incidental or consequential damages related to the user’s decision to use this information contained herein.